Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer.

ABSTRACT:

Background

Exploring novel therapeutic targets and developing targeted therapies constitute an urgent clinical need for improving the prognosis of ovarian cancer (OC), particularly among patients with advanced stages. Currently, chimeric antigen receptor T (CAR-T) cell therapy has been demonstrated to have a remarkable therapeutic effect in hematological malignancies, while its application remains limited in OC due to the absence of appropriate target molecules and the complex immunosuppressive tumor microenvironment (TME). Poliovirus receptor (PVR, CD155) has been the subject of extensive research in the field of regulatory molecules within the immune microenvironment. However, there has been a paucity of research investigating its role in OC. Receptor tyrosine kinase-like orphan

SUBMITTER: Ye Y 

PROVIDER: S-EPMC12847607 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature